VNRX

VolitionRx Limited (VNRX) - 10-Q Summary for Period Ended September 30, 2024

Business Context and Reporting Period

This report covers the quarterly period ended September 30, 2024, and the nine months ended on that date. VolitionRx Limited is a multi-national epigenetics company focused on developing diagnostic tests for cancer and diseases associated with NETosis (such as sepsis) using nucleosome biomarkers. The company operates through subsidiaries globally and relies on licensing agreements and third-party distributors (e.g., Heska/Antech, IDEXX) for commercialization of its Nu.Q® Vet Cancer Test.

Key Financial Metrics

Material Changes vs. Prior Comparable Period

• Revenue Growth: Total revenues increased significantly year-over-year. For the nine months ended September 30, 2024, revenue was $1.04 million compared to $0.53 million in the prior year period (a 96% increase). This growth was driven primarily by product sales of key components for the Nu.Q® Vet Cancer Test to Antech (formerly Heska) and Nu.Q® Discover services.
• Expense Reduction: Total operating expenses decreased by 20% to $22.3 million for the nine-month period compared to $27.8 million in the prior year. This reduction was due to lower personnel expenses, reduced clinical trial activity, and decreased stock-based compensation.
• Net Loss Improvement: The net loss narrowed to $21.4 million for the nine months ended September 30, 2024, compared to $26.9 million in the same period in 2023.
• Capital Raise: In August 2024, the company completed a registered direct offering raising approximately $6.4 million in net proceeds through the sale of common stock, pre-funded warrants, and common warrants.

Guidance, Outlook, Risks, and Contingencies

• Going Concern: Management has concluded that there is substantial doubt about the company's ability to continue as a going concern for one year from the date of the report. The company has incurred operating losses since inception and expects to incur further losses. Continued operations depend on obtaining additional financing through equity, debt, or licensing agreements.
• Liquidity: As of September 30, 2024, cash and cash equivalents were $5.4 million. The company plans to use reserves for R&D and commercialization but may need to raise additional capital to sustain operations.
• Internal Controls: The company identified a material weakness in internal control over financial reporting, specifically regarding insufficient written documentation of policies and procedures. Remediation efforts are ongoing.
• Commitments: The company has significant future payment obligations, including approximately $1.23 million in collaborative research agreements and $5.88 million in total long-term debt payments (including interest) over the next several years.
• Outlook: The company is transitioning from a research stage to commercialization. Future success depends on the acceptance of its products, regulatory approvals, and the ability to monetize intellectual property through licensing.

Key Facts for Investor Verification

• Cash Runway: Verify the sufficiency of the $5.4 million cash balance against the $20.5 million operating cash burn over the last nine months and upcoming debt/research obligations.
• Revenue Concentration: Confirm the sustainability of revenue growth, which is heavily reliant on sales to a single major partner (Antech/Heska) for the Nu.Q® Vet Cancer Test.
• Financing Needs: Assess the likelihood and terms of future capital raises required to address the "substantial doubt" regarding going concern status.
• Internal Control Remediation: Monitor progress on fixing the material weakness in internal controls to ensure future financial reporting reliability.
• Debt Obligations: Review the maturity schedule of the ~$4.8 million in long-term debt and the ability to service these obligations without further dilution or asset liquidation.